Long-term gamma-aminobutyric acid (GABA) treatment fails to regain beta-cell function in longstanding type 1 diabetes in a randomized trial

Long-term gamma-aminobutyric acid (GABA) treatment fails to regain beta-cell function in longstanding type 1 diabetes in a randomized trial

Abstract Gamma-amino butyric acid (GABA) has in experimental studies been found to promote beta-cell proliferation, enhance insulin secretion and reduce inflammation, positioning it as a candidate drug for type 1 diabetes (T1D) therapy. This phase I/II randomized controlled trial assessed the safety...

Full description

Saved in:
Bibliographic Details
Main Authors: Henrik Hill, Per Lundkvist, Georgios Tsatsaris, Bryndis Birnir, Daniel Espes, Per-Ola Carlsson
Format: Article
Language:English
Published: Nature Portfolio 2025-04-01
Series:Scientific Reports
Subjects:
Type 1 diabetes
GABA
Beta-Cell
Oral therapy
Regenerative therapy
Online Access:https://doi.org/10.1038/s41598-025-95751-y
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1038/s41598-025-95751-y

Similar Items